NHS England has set up a team that will plan how to roll out promising new drugs even as they wait to be approved by regulators, the chief executive of the health service has said.
It comes after new drug donanemab was found to slow cognitive and functional decline associated with Alzheimer’s by about 35% in a late-stage phase 3 clinical trial earlier this year.
